These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 16507121

  • 1. Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis.
    Zwerina J, Tuerk B, Redlich K, Smolen JS, Schett G.
    Arthritis Res Ther; 2006; 8(1):R22. PubMed ID: 16507121
    [Abstract] [Full Text] [Related]

  • 2. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.
    Redlich K, Görtz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G.
    Am J Pathol; 2004 Feb; 164(2):543-55. PubMed ID: 14742260
    [Abstract] [Full Text] [Related]

  • 3. R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway.
    Krönke G, Uderhardt S, Kim KA, Stock M, Scholtysek C, Zaiss MM, Surmann-Schmitt C, Luther J, Katzenbeisser J, David JP, Abdollahi-Roodsaz S, Tran K, Bright JM, Binnerts ME, Akhmetshina A, Böhm C, Distler JH, Joosten LA, Schett G, Abo A.
    Arthritis Rheum; 2010 Aug; 62(8):2303-12. PubMed ID: 20506554
    [Abstract] [Full Text] [Related]

  • 4. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R, Wetterwald A, Portenier J, Dolder S, Mueller C, Hofstetter W.
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [Abstract] [Full Text] [Related]

  • 5. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
    Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G.
    Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
    [Abstract] [Full Text] [Related]

  • 6. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS.
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH, Gückel E, Schett G, Voll RE, Zwerina J.
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [Abstract] [Full Text] [Related]

  • 8. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
    Saito H, Kojima T, Takahashi M, Horne WC, Baron R, Amagasa T, Ohya K, Aoki K.
    Arthritis Rheum; 2007 Apr; 56(4):1164-74. PubMed ID: 17393436
    [Abstract] [Full Text] [Related]

  • 9. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D.
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [Abstract] [Full Text] [Related]

  • 10. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
    Zhang Q, Badell IR, Schwarz EM, Boulukos KE, Yao Z, Boyce BF, Xing L.
    Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.
    Schett G, Stolina M, Dwyer D, Zack D, Uderhardt S, Krönke G, Kostenuik P, Feige U.
    Arthritis Rheum; 2009 Sep; 60(9):2644-54. PubMed ID: 19714640
    [Abstract] [Full Text] [Related]

  • 12. Erosive arthritis.
    Schett G.
    Arthritis Res Ther; 2007 Sep; 9 Suppl 1(Suppl 1):S2. PubMed ID: 17634141
    [Abstract] [Full Text] [Related]

  • 13. Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis.
    Geboes L, De Klerck B, Van Balen M, Kelchtermans H, Mitera T, Boon L, De Wolf-Peeters C, Matthys P.
    Arthritis Rheum; 2007 Aug; 56(8):2595-607. PubMed ID: 17665444
    [Abstract] [Full Text] [Related]

  • 14. JNK1 is not essential for TNF-mediated joint disease.
    Köller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G.
    Arthritis Res Ther; 2005 Aug; 7(1):R166-73. PubMed ID: 15642137
    [Abstract] [Full Text] [Related]

  • 15. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.
    Blüml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, Schett G, Scheinecker C, Kollias G, Selzer E, Bilban M, Smolen JS, Superti-Furga G, Redlich K.
    Arthritis Rheum; 2010 Jun; 62(6):1608-19. PubMed ID: 20155834
    [Abstract] [Full Text] [Related]

  • 16. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
    Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G.
    Arthritis Rheum; 2007 Jan; 56(1):79-88. PubMed ID: 17195210
    [Abstract] [Full Text] [Related]

  • 17. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
    Schurigt U, Hummel KM, Petrow PK, Gajda M, Stöckigt R, Middel P, Zwerina J, Janik T, Bernhardt R, Schüler S, Scharnweber D, Beckmann F, Saftig P, Kollias G, Schett G, Wiederanders B, Bräuer R.
    Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
    [Abstract] [Full Text] [Related]

  • 18. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation.
    Görtz B, Hayer S, Redlich K, Zwerina J, Tohidast-Akrad M, Tuerk B, Hartmann C, Kollias G, Steiner G, Smolen JS, Schett G.
    J Bone Miner Res; 2004 Jun; 19(6):990-8. PubMed ID: 15125796
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
    Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G.
    Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
    [Abstract] [Full Text] [Related]

  • 20. Autoimmunity and bone.
    Schwarz EM, Looney RJ, Drissi MH, O'Keefe RJ, Boyce BF, Xing L, Ritchlin CT.
    Ann N Y Acad Sci; 2006 Apr; 1068():275-83. PubMed ID: 16831928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.